Nectar Lifesciences enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


201	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
13.0	13.0	19.8	20.3	17.9
0.0	0.0	582	636	754
188	—	—	—	—
−13.0	−13.0	562	615	736
₹9.67	—	—	—	—

582	582	1,538	1,705	1,818
0.0%	0.0%	37.8%	37.3%	41.5%

37.50×	—	—	—	—
−2.11×	—	—	—	—
−2.10×	—	—	—	—
5.0	0.0	1,673	1,686	1,525
−89.2	−60.7	−26.5	153	53.9
−89.7	−61.0	−88.8	92.4	−5.2
—	−349	169	225	134
−361	−361	126	195	104
—	−374	104	143	69.4
—	12.3	43.8	29.4	30.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NECLIFE₹10.34

Nectar Lifesciences Limited

· Pharma & Health

₹ CrorePeersAAREYDRUGS NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹201 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	200.9
- Cash, Equiv & ST Investments	17.9	20.3	19.8	13.0	13.0
+ Total Debt	753.8	635.5	582.0	0.0	0.0
Enterprise Value	—	—	—	—	187.9
Net Debt (memo)	735.9	615.2	562.3	-13.0	-13.0
EV per Share	—	—	—	—	9.67

Total Capital	1,818.4	1,704.8	1,538.1	582.3	582.3
Total Debt/Total Capital	41.46	37.28	37.84	0.00	0.00

EV/Sales	—	—	—	—	37.50
EV/EBITDA	—	—	—	—	-2.11
EV/EBIT	—	—	—	—	-2.10
Reference Items — Trailing FY Values
Sales	1,524.6	1,685.6	1,673.1	0.0	5.0
EBITDA	53.9	153.1	-26.5	-60.7	-89.2
EBIT	-5.2	92.4	-88.8	-61.0	-89.7
Operating Cash Flow	133.7	224.7	169.4	-348.7	—
Free Cash Flow	103.6	195.3	125.6	-361.0	-361.0
FCFF (free cash flow to the firm)	69.4	143.0	103.5	-373.5	—
Capital Expenditure	30.1	29.4	43.8	12.3	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.